



Press Release

MSN Labs ushers a ray of hope for renal cancer patients in India. Launches Cabolong™ – country's first branded generic of Cabozantinib for treatment of renal cell carcinoma

Hyderabad, 23 September 2021: MSN Labs, one of the fastest growing, research-based and fully integrated pharmaceutical company has marked the unveiling of its new & dedicated Oncology Division, 'Oncology Original Medicine' by launching **Cabolong™ - India's first branded generic of Cabozantinib for treatment of renal cell carcinoma.**

The division will focus on presenting a comprehensive range of affordable High quality, Bio-Equivalent generic oncology medicines benefitting patients in India. MSN already holds a distinguished track record of launching early branded generics of 14 Oncology molecules and making its presence felt in the US, Europe and emerging markets.

This initiative comes at a crucial juncture wherein the cancer cases in the country are likely to increase to 15.6 lakhs by 2025 — a 12% increase from current estimated cases — based on current trends, according to the National Cancer Registry Programme Report 2020.

“Our endeavour at MSN Labs has always been to enable swift access to affordable life-saving medicines in critical therapeutic domains. Given the rising cancer incidence in our country and overwhelming treatment costs associated with it, launch of our dedicated oncology division demonstrates our unwavering commitment to patients' health and economic well-being.” MSN Group commented on the occasion.

Cabolong™, available in 20mg/40mg/60mg strengths at the most affordable pricing of below INR 10,000 (Ten Thousand Rupees) for monthly treatment regimen with the highest strength, will hugely benefit Indian patients. The same therapy presently runs into Lakhs with imported brands currently available in the market.

Cabolong™ is manufactured at MSN Labs' state-of-the-art facility approved by stringent global regulatory authorities like US FDA and EU GMP. Recognized as the most innovative company to launch new molecules at affordable prices, MSN Labs also has an established presence in major therapeutic segments like Cardiology, Diabetology, Pain, CNS, Urology and Gastroenterology, etc.

For more information and availability of Cabolong™, contact customer care@msnlabs.com.

END

**About MSN Group:**

MSN Group is the fastest growing research-based and vertically integrated pharmaceutical company headquartered in Hyderabad, India. Founded in 2003 with a mission to make healthcare affordable, MSN has nine API and five finished dosage facilities in India & USA. The Group has an integrated R&D center for both API and formulation under one roof, dedicated to research and development of pharmaceuticals. With its core focus on speed and consistency in delivery, MSN has achieved more than 650 national and international patents, over 130 ANDAs, and emerged as world no. 1 in active US DMF filings. The company, with a product portfolio of 450+ APIs and 300+ formulations spanning 35 major therapies, has won the trust of more than 40 million patients in 65 countries across the world.

For more information on Oncology offerings, reach out to customercare@msnlabs.com. For information on MSN Labs, please visit www.msnlabs.com

MSN Labs Media Contact:

PVR Surya Kanth

Corporate Communications

Mobile: +91 8790829841

E-mail: pvr.suryakanth@msnlabs.com